Wednesday 6-18-2014 Merck & Company (MRK) $MRK opened at 58.03 hitting the high price of 58.45 and a day low of 57.81 with a total volume of 7,837,250. MRK had a previous close of 58.06 and has been seeing an average volume of 7,801,820.
Overall Average: 72% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Down 14%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jun 18, 5:02PM CDT
Endocyte shares got hammered today on the disappointing news that partner Merck decided to hand back rights to vintafolide and leave the company to go it alone. Endocyte is waiting for more data from a phase 2b trial in non-small cell lung... (full story)
World Glioblastoma Multiforme Therapeutics Market to Reach USD 583 Mln in 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Jun 18, 1:03PM CDT
Owing to the poor prognosis under presently available treatment options, therapies with high potency are in strong demand in the world glioblastoma multiforme (GBM) market. In newly diagnosed patients, the present standard of care, encompassing radiation therapy, resection surgery and chemotherapy with Merck's Temodar, has a maximum overall survival (OS) of fifteen months and almost inevitable tumor recurrence. Presently available therapeutic options for recurrent GBM are carmustine, Roche's Avastin (bevacizumab) and some other chemotherapy drugs used in off-label ways. However, these therapies merely provide limited OS benefit, thus leaving high unmet need in this patient pool. (full story)
Merck Backs Out of Endocyte Vintafolide Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 11:10AM CDT
Endocyte, Inc. (ECYT) announced that it has regained worldwide rights to oncology candidate, vintafolide, as Merck decided to discontinue its investment in the development of vintafolide. (full story)
Global Sample Preparation Market 2014-2018 by Product (Instruments, Consumables, Kits), Application (Genomics, Proteomics) & End Users (Molecular Diagnostics)
M2 - Wed Jun 18, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk6xn/sample) has announced the addition of the "Global Sample Preparation Market 2014-2018 by Product (Instruments, Consumables, Kits), Application (Genomics, Proteomics) & End Users (Molecular Diagnostics)" report to their offering. The global sample preparation market is segmented on the basis of products, applications, and end users. Based on products the global market includes instruments, consumables, accessories and kits. Instruments are further classified into sample preparation workstations, liquid handling systems, extraction systems and others. Liquid handling systems comprises liquid handling workstations, pipetting systems, reagent dispensers, microplate washers and others. The consumables comprise filters, columns, tubes, plates and others. Accessories include caps, disposable bags/box, rod covers, adapters, tip and tube holder, plate carrier. Sample Preparation kits further segmented into Purification kits (DNA, RNA, Nucleic Acid and Protein), Extraction kits (DNA, RNA, Nucleic Acid and Protein), Isolation kits (DNA, RNA, Nucleic Acid and Protein), and others (Cell Lysis kits and Clean- up kits). Based on applications the global sample preparation market is broadly categorized into genomics, proteomics, epigenomics and others. Based on geography, the market is divided into North America, Europe, Asia, and the Rest of World (ROW). The market by end users segmented into molecular diagnostics, pharmaceuticals & biotechnology, applied testing, and academic research institutes. In 2013, the molecular diagnostics accounted for the largest share of the global market, by end users. A number of factors such as technological advancements in workstations, global alliances amongst leading research institutes to boost drug discovery, increasing life science and R&D spending, technological advancements in analytical instruments are propelling the growth of the sample preparation market. However, difficulty in developing one-size-fits-all' kits and high costs of workstations are the major factors hindering the growth of this market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Sample Preparation Market, By Product 5 Sample Preparation Market, By Application 6 Sample Preparation Market, By End User 7 Sample Preparation Market, By Geography 8 Competitive Landscape 9 Company Profiles - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Danaher Corporation - Hamilton Company - Illumina, Inc - Merck Millipore - Norgen Biotek Corporation - Perkinelmer, Inc. - Qiagen N.V. - Roche Applied Science - Sigma-Aldrich Corporation - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/kkk6xn/sample (full story)
Schizophrenia Drug Market & Pipeline Report 2014
M2 - Wed Jun 18, 8:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbcgw5/schizophrenia) has announced the addition of the "Schizophrenia Drug Market & Pipeline Insight" report to their offering. Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market. The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously, offers much potential for future prevention and cure over the next two decades. Schizophrenia Drug Market & Pipeline Insight: - Schizophrenia Drug Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug in Clinical Development Phase: 143 - Majority Therapies in Preclinical Phase: 65 - Marketed Schizophrenia Drugs: 16 - Suspended & Discontinued Drug Profiles: 163 - Competitive Landscape Key Topics Covered: 1. Schizophrenia Drug Market Overview 2. Schizophrenia Drugs Clinical Pipeline by Phase & Country 3. Marketed Schizophrenia Drugs Clinical Insight & Patent Analysis 4. Suspended & Discontinued Schizophrenia Drug Profile 5. Competitive Landscape 5.1 Abbott Laboratories 5.2 Addex Pharmaceuticals 5.3 Astellas Pharma 5.4 Dainippon Sumitomo Pharma 5.5 Eli Lilly 5.6 GlaxoSmithKline 5.7 Johnson & Johnson 5.8 Merck 5.9 Pfizer 5.10 Roche 5.11 Sanofi For more information visit http://www.researchandmarkets.com/research/xb...izophrenia (full story)
Wednesday’s Top Biotech Stories: Insmed, Endocyte, and GW Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 18, 8:10AM CDT
Let's take a closer look at three major biotech headlines this Wednesday morning -- Insmed 's new breakthrough therapy designation, the end of Endocyte 's partnership with Merck , and a new stock offering from GW Pharmaceuticals . Insmed... (full story)
Stock Futures Hold Narrow Gains; Adobe Systems Up On Q2 Results
at Investor's Business Daily - Wed Jun 18, 8:01AM CDT
Stock futures were positive, but not by much, ahead of Wednesday's open. Dow futures held 2.5 points above fair market value. Nasdaq 100 futures were ahead 4.2 points. S&P 500 futures clung to a 0.2% advance. Small caps lagged, with the Russell 2000... (full story)
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been... (full story)
Endocyte regains worldwide rights to vintafolide from Merck in all indications
M2 - Wed Jun 18, 5:40AM CDT
Biopharmaceutical company Endocyte (NasdaqGS:ECYT) disclosed on Tuesday that it has regained the worldwide rights to vintafolide in all indications, including ovarian cancer and non-small cell lung cancer, from Merck. (full story)
2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human (full story)
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
M2 - Wed Jun 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7l3m2/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. The global prophylactic human papillomavirus (HPV) vaccine market value is forecast to experience moderate growth over the coming years, climbing from $1.7 billion in 2012 to $2.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.6%, says a new report from research and consulting firm The authors. Out of the nine major markets (9MM: the US, Canada, France, Germany, Italy, Spain, the UK, Japan and Australia), HPV vaccine sales in Canada and Australia are expected to grow at the largest CAGRs of over 9% during the forecast period. This will be driven by the launch of Merck's V503 vaccine and the inclusion of males in routine HPV vaccine recommendations. Claire Herman, says: Recognizing both the role of HPV in other non-cervical cancers and the benefits of herd immunity has led to a greater emphasis on vaccinating both males and females. A shift away from a sole focus on cervical cancer in females appears to have benefited Merck, as its Gardasil vaccine provides protection against two additional HPV types, which are responsible for genital warts in males and females. However, the global market for prophylactic HPV vaccines is marked by substantial obstacles to growth, namely low coverage rates and fears over vaccine safety. Additionally, a major clinical unmet need regarding current HPV vaccines is the limited number of HPV types against which they protect. The authors believes that Merck's upcoming nine-valent pipeline vaccine V503 is well placed to capitalize on this need, with sales forecast to reach $1.5 billion in the US alone by 2022, representing a massive 95% market share. Key opinion leaders from across the 9MM expect V503 to be widely used, essentially displacing Merck's own Gardasil. However, it was noted that an inflated price, relative to current HPV vaccines, could present a barrier to uptake. Other non-clinical factors that will affect the vaccine's adoption include low awareness of HPV vaccination and the stigma surrounding the vaccination of adolescents against a sexually-transmitted virus, Herman concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Vaccination Recommendations and Coverage Rates 5 Competitive Assessment - Gardasil - Cervarix 6 Unmet Need and Opportunity - Protection against Multiple HPV Types - Vaccine Coverage Rates - Perception of Vaccine Safety - Awareness of HPV Vaccination - Affordability of HPV Vaccines - Coverage of HPV Types Prevalent in Certain Populations - Vaccine Compliance Rates - Lifelong Protection from HPV Infection Not Established - Ongoing Need for Cervical Cancer Screening 7 Pipeline Assessment - Clinical Trial Mapping - Promising Vaccines in Clinical Development - Innovative HPV Vaccines in Early Development 8 Current and Future Players - Merck - GSK 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/n7...harmapoint (full story)
Why Endocyte Inc. Shares Plummeted in After Hours
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 17, 7:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company... (full story)
Is Roche's Dividend In Danger?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 17, 5:00PM CDT
Swiss giant Roche swims in treacherous waters. The pharmaceutical industry can be a challenging place to operate, as companies must spend $1 billion or more to develop a new drug and a majority of those that are put into... (full story)
Merck drops development of Endocyte cancer drug
AP - Tue Jun 17, 4:30PM CDT
NEW YORK (AP) — Biotech drugmaker Endocyte said Tuesday it has regained rights to an experimental cancer drug from Merck & Co., after the treatment failed in a key study last month. (full story)
Endocyte Regains Worldwide Rights to Vintafolide
GlobeNewswire - Tue Jun 17, 3:01PM CDT
Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide. (full story)
HPV Infections Vaccine Pipeline Analyzed by PNS Pharma in Its New Research Report Published at MarketPublishers.com
PRWeb - Tue Jun 17, 1:20PM CDT
Human papillomaviruses represent a group of over 150 viruses which are related to each other, with certain types of viruses being able to cause warts (papillomas). There exist only two human papillomavirus vaccines which are currently marketed worldwide. Both these vaccines are prepared with the use of the recombinant technology, which is taken from purified L1 structural proteins that self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). (full story)
Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the... (full story)
The Zacks Analyst Blog Highlights: AbbVie, Gilead, Merck and Idenix Pharmaceuticals
PR Newswire - Tue Jun 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Gilead (Nasdaq:GILD-Free Report), Merck (NYSE:MRK-Free Report) and Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX-Free Report). (full story)
Global Respiratory Devices Market Report 2014: Inhalers, Nebulizers, Airways, Masks, Sleep Apnea, Oxygen Therapy, Ventilators Medical Humidifiers, Respiratory Measurement)
M2 - Tue Jun 17, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hk98cb/the_worldwide) has announced the addition of the "The Worldwide Market for Respiratory Devices (Inhalers, Nebulizers, Airways, Masks, Sleep Apnea, Oxygen Therapy, Ventilators Medical Humidifiers, Respiratory Measurement)" report to their offering. The worldwide respiratory device market continues to grow despite economic downturns mainly due to the aging of the world population and increasing incidence of COPD. The market encompasses many different products to help treat and monitor respiratory conditions as well as many large and small manufacturers. This report provides exhaustive market coverage, including estimates and forecasts for the following devices: - Inhalers - Inhalers, device-only market - Nebulizers, Jet - Nebulizers, Ultrasonic - Airway Masks - Cannula - Tracheostomy Tubes - Sleep Apnea CPAP - Sleep Apnea Bi-Level - Sleep Apnea Facial Interface - Sleep Apnea APAP - Oxygen Concentrators - Oxygen Systems - Ventilators - Humidifiers - Respiratory Measurement Devices (Oximeters, Capnograph, Others) - Resuscitators Companies Profiled in this Report Include: - Airsep - Astrazeneca - Boehringer ingelheim gmbh - Covidien - Devilbiss Healthcare - Fisher & paykel healthcare - Ge healthcare - Glaxosmithkline - Invacare - Maquet medical systems - Medline - Merck & company, inc. - Omron healthcare - Pari respiratory equipment, inc. - Philips/respironics - Resmed - Smiths Medical - Spirometrics - Teleflex For more information visit http://www.researchandmarkets.com/research/hk..._worldwide (full story)
Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments
M2 - Tue Jun 17, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4bxgz/healthcare) has announced the addition of the "Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments" report to their offering. Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments Infections from activities and procedures taking place within a healthcare facility have become a cause for great concern. These infection may occur in a postoperative wound or as a complication unrelated to the disease or condition. This report, Healthcare-Associated Infection (HAI) Control Markets: focuses on the market opportunities for companies that can assist hospitals and other healthcare facilities with important HAI mitigation tasks including: preventing, testing and treating infections in the healthcare environment. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This is driving the demand for products and services. Prevention, Testing and Treatment and will provide a market analysis for each of the important segments: - Disinfection - Wide-Area Sterilization - Device Sterilization - HAI Testing ' C.diff - HAI Testing ' MRSA - HAI Testing - Others - HAI Treatment 'Antibiotic Products As part of the report's coverage, the following trends are discussed: - Nosocomial Infection Statistics - Affordable Care Act (ACA) Funding - Populations at Risk for Infection - Infection Risk Assessments by Hospital Department - Increased Hospital Length of Stay for HAIs - International Trends in Nursing Facilities - U.S. Government's National Plan to Prevent Healthcare - Government Funding for HAI Prevention Infrastructure Activities - Israel Reduction in HAIs - Arizona Prevention Study - Connecticut Funding for HAI Prevention and Reporting - Pennsylvania Study of HAI Admissions and Readmissions - Infections and Drug Resistance - Screening Trends - Trends in Partnerships and Alliances - Current Burden of HAI Statistics The following companies are profiled in this report: - Advanced Sterilization Products - Becton, Dickinson and Company - Belimed - bioMerieux - Cantel - Cepheid - Getinge Group - Kimberly-Clark - Merck & Co - Nordion - Pfizer - Roche - Sakura Seiki - Steris - Tso3 For more information visit http://www.researchandmarkets.com/research/w4bxgz/healthcare (full story)
Overall Average: 72% Buy
Recent stock forum discussions about MRK http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Down 14%: Is Endocyte a Bad News Buy?
Michael Douglass and David Williamson, The Motley Fool - Motley Fool - Wed Jun 18, 5:02PM CDT
Endocyte shares got hammered today on the disappointing news that partner Merck decided to hand back rights to vintafolide and leave the company to go it alone. Endocyte is waiting for more data from a phase 2b trial in non-small cell lung... (full story)
World Glioblastoma Multiforme Therapeutics Market to Reach USD 583 Mln in 2019, States GBI Research in Its Report Published at MarketPublishers.com
PRWeb - Wed Jun 18, 1:03PM CDT
Owing to the poor prognosis under presently available treatment options, therapies with high potency are in strong demand in the world glioblastoma multiforme (GBM) market. In newly diagnosed patients, the present standard of care, encompassing radiation therapy, resection surgery and chemotherapy with Merck's Temodar, has a maximum overall survival (OS) of fifteen months and almost inevitable tumor recurrence. Presently available therapeutic options for recurrent GBM are carmustine, Roche's Avastin (bevacizumab) and some other chemotherapy drugs used in off-label ways. However, these therapies merely provide limited OS benefit, thus leaving high unmet need in this patient pool. (full story)
Merck Backs Out of Endocyte Vintafolide Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 11:10AM CDT
Endocyte, Inc. (ECYT) announced that it has regained worldwide rights to oncology candidate, vintafolide, as Merck decided to discontinue its investment in the development of vintafolide. (full story)
Global Sample Preparation Market 2014-2018 by Product (Instruments, Consumables, Kits), Application (Genomics, Proteomics) & End Users (Molecular Diagnostics)
M2 - Wed Jun 18, 9:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kkk6xn/sample) has announced the addition of the "Global Sample Preparation Market 2014-2018 by Product (Instruments, Consumables, Kits), Application (Genomics, Proteomics) & End Users (Molecular Diagnostics)" report to their offering. The global sample preparation market is segmented on the basis of products, applications, and end users. Based on products the global market includes instruments, consumables, accessories and kits. Instruments are further classified into sample preparation workstations, liquid handling systems, extraction systems and others. Liquid handling systems comprises liquid handling workstations, pipetting systems, reagent dispensers, microplate washers and others. The consumables comprise filters, columns, tubes, plates and others. Accessories include caps, disposable bags/box, rod covers, adapters, tip and tube holder, plate carrier. Sample Preparation kits further segmented into Purification kits (DNA, RNA, Nucleic Acid and Protein), Extraction kits (DNA, RNA, Nucleic Acid and Protein), Isolation kits (DNA, RNA, Nucleic Acid and Protein), and others (Cell Lysis kits and Clean- up kits). Based on applications the global sample preparation market is broadly categorized into genomics, proteomics, epigenomics and others. Based on geography, the market is divided into North America, Europe, Asia, and the Rest of World (ROW). The market by end users segmented into molecular diagnostics, pharmaceuticals & biotechnology, applied testing, and academic research institutes. In 2013, the molecular diagnostics accounted for the largest share of the global market, by end users. A number of factors such as technological advancements in workstations, global alliances amongst leading research institutes to boost drug discovery, increasing life science and R&D spending, technological advancements in analytical instruments are propelling the growth of the sample preparation market. However, difficulty in developing one-size-fits-all' kits and high costs of workstations are the major factors hindering the growth of this market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Sample Preparation Market, By Product 5 Sample Preparation Market, By Application 6 Sample Preparation Market, By End User 7 Sample Preparation Market, By Geography 8 Competitive Landscape 9 Company Profiles - Agilent Technologies, Inc. - Bio-Rad Laboratories, Inc. - Danaher Corporation - Hamilton Company - Illumina, Inc - Merck Millipore - Norgen Biotek Corporation - Perkinelmer, Inc. - Qiagen N.V. - Roche Applied Science - Sigma-Aldrich Corporation - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/kkk6xn/sample (full story)
Schizophrenia Drug Market & Pipeline Report 2014
M2 - Wed Jun 18, 8:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xbcgw5/schizophrenia) has announced the addition of the "Schizophrenia Drug Market & Pipeline Insight" report to their offering. Though schizophrenia has been in the realm of research for over a century, the actual cause of the disorder still remains unknown. Pharmacological treatments have been in wide use for many years. However, there is hardly any evidence that these treatments have significantly improved outcomes for most people with schizophrenia. The pharmaceutical companies in this market are currently facing and are expected to continue to face stiff competition from many generic atypical antipsychotics. The major target of differentiating the products through improved treatment of negative or cognitive symptoms, partial responders, as well as improved tolerability, and demonstration of cost-effectiveness are essential have become the main focus of the pharma companies in this market. The future years are likely to witness a shift in the way in which this disease is perceived. With schizophrenia being considered as a neuro developmental disorder with psychosis as a late stage of illness, it is likely that the current unsatisfactory outcomes could change. Such new ideas of looking into schizophrenia as a neuro developmental disorder, which is substantially different from the way it has been treated previously, offers much potential for future prevention and cure over the next two decades. Schizophrenia Drug Market & Pipeline Insight: - Schizophrenia Drug Market Overview - Marketed Drug Profiles & Patent Analysis - Clinical Trial Insight by Phase & Country - Drug in Clinical Development Phase: 143 - Majority Therapies in Preclinical Phase: 65 - Marketed Schizophrenia Drugs: 16 - Suspended & Discontinued Drug Profiles: 163 - Competitive Landscape Key Topics Covered: 1. Schizophrenia Drug Market Overview 2. Schizophrenia Drugs Clinical Pipeline by Phase & Country 3. Marketed Schizophrenia Drugs Clinical Insight & Patent Analysis 4. Suspended & Discontinued Schizophrenia Drug Profile 5. Competitive Landscape 5.1 Abbott Laboratories 5.2 Addex Pharmaceuticals 5.3 Astellas Pharma 5.4 Dainippon Sumitomo Pharma 5.5 Eli Lilly 5.6 GlaxoSmithKline 5.7 Johnson & Johnson 5.8 Merck 5.9 Pfizer 5.10 Roche 5.11 Sanofi For more information visit http://www.researchandmarkets.com/research/xb...izophrenia (full story)
Wednesday’s Top Biotech Stories: Insmed, Endocyte, and GW Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Jun 18, 8:10AM CDT
Let's take a closer look at three major biotech headlines this Wednesday morning -- Insmed 's new breakthrough therapy designation, the end of Endocyte 's partnership with Merck , and a new stock offering from GW Pharmaceuticals . Insmed... (full story)
Stock Futures Hold Narrow Gains; Adobe Systems Up On Q2 Results
at Investor's Business Daily - Wed Jun 18, 8:01AM CDT
Stock futures were positive, but not by much, ahead of Wednesday's open. Dow futures held 2.5 points above fair market value. Nasdaq 100 futures were ahead 4.2 points. S&P 500 futures clung to a 0.2% advance. Small caps lagged, with the Russell 2000... (full story)
Allergan, Actavis Top Big Cap Pharmas Amid M&A Flurry
at Investor's Business Daily - Wed Jun 18, 7:02AM CDT
With 2014 already the strongest year for mergers and acquisitions since 2007, the flurry of dealmaking has given shares of some large drugmakers a shot in the arm -- or face, in the case of Botox maker Allergan (AGN). But not all offers have been... (full story)
Endocyte regains worldwide rights to vintafolide from Merck in all indications
M2 - Wed Jun 18, 5:40AM CDT
Biopharmaceutical company Endocyte (NasdaqGS:ECYT) disclosed on Tuesday that it has regained the worldwide rights to vintafolide in all indications, including ovarian cancer and non-small cell lung cancer, from Merck. (full story)
2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019
M2 - Wed Jun 18, 5:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d66cdt/human) has announced the addition of the "2014 Report on the International Human Reproductive Technologies Market - Forecast to 2019" report to their offering. This report covers the market analysis for various drugs, devices and treatment technologies used in assistance and to control human reproduction. The stakeholders for this study include manufacturers and providers of contraceptive technologies and infertility solutions. The market overview section of the report demonstrates the market dynamics and trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global human reproductive technologies market. The global human reproductive technologies market is categorized on the basis of various infertility treatments and contraceptive technologies. The infertility technologies market is analyzed in this report with respect to drugs as well as types of treatment procedures. With respect to drugs, the report includes leading brands (by sales) from three major classes, namely, gonadotropins, androgens and erectile dysfunction. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Human Reproduction Technologies Market, by Infertility Treatment Chapter 5 Global Human Reproductive Technologies Market, by Contraceptive Technologies Chapter 6 Global Human Reproductive Technologies Market Revenue, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/d66cdt/human (full story)
PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022
M2 - Wed Jun 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/n7l3m2/pharmapoint) has announced the addition of the "PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Global Drug Forecast and Market Analysis to 2022" report to their offering. The global prophylactic human papillomavirus (HPV) vaccine market value is forecast to experience moderate growth over the coming years, climbing from $1.7 billion in 2012 to $2.2 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 2.6%, says a new report from research and consulting firm The authors. Out of the nine major markets (9MM: the US, Canada, France, Germany, Italy, Spain, the UK, Japan and Australia), HPV vaccine sales in Canada and Australia are expected to grow at the largest CAGRs of over 9% during the forecast period. This will be driven by the launch of Merck's V503 vaccine and the inclusion of males in routine HPV vaccine recommendations. Claire Herman, says: Recognizing both the role of HPV in other non-cervical cancers and the benefits of herd immunity has led to a greater emphasis on vaccinating both males and females. A shift away from a sole focus on cervical cancer in females appears to have benefited Merck, as its Gardasil vaccine provides protection against two additional HPV types, which are responsible for genital warts in males and females. However, the global market for prophylactic HPV vaccines is marked by substantial obstacles to growth, namely low coverage rates and fears over vaccine safety. Additionally, a major clinical unmet need regarding current HPV vaccines is the limited number of HPV types against which they protect. The authors believes that Merck's upcoming nine-valent pipeline vaccine V503 is well placed to capitalize on this need, with sales forecast to reach $1.5 billion in the US alone by 2022, representing a massive 95% market share. Key opinion leaders from across the 9MM expect V503 to be widely used, essentially displacing Merck's own Gardasil. However, it was noted that an inflated price, relative to current HPV vaccines, could present a barrier to uptake. Other non-clinical factors that will affect the vaccine's adoption include low awareness of HPV vaccination and the stigma surrounding the vaccination of adolescents against a sexually-transmitted virus, Herman concludes. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Vaccination Recommendations and Coverage Rates 5 Competitive Assessment - Gardasil - Cervarix 6 Unmet Need and Opportunity - Protection against Multiple HPV Types - Vaccine Coverage Rates - Perception of Vaccine Safety - Awareness of HPV Vaccination - Affordability of HPV Vaccines - Coverage of HPV Types Prevalent in Certain Populations - Vaccine Compliance Rates - Lifelong Protection from HPV Infection Not Established - Ongoing Need for Cervical Cancer Screening 7 Pipeline Assessment - Clinical Trial Mapping - Promising Vaccines in Clinical Development - Innovative HPV Vaccines in Early Development 8 Current and Future Players - Merck - GSK 9 Market Outlook 10 Appendix For more information visit http://www.researchandmarkets.com/research/n7...harmapoint (full story)
Why Endocyte Inc. Shares Plummeted in After Hours
Sean Williams, The Motley Fool - Motley Fool - Tue Jun 17, 7:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endocyte , a biopharmaceutical company... (full story)
Is Roche's Dividend In Danger?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Tue Jun 17, 5:00PM CDT
Swiss giant Roche swims in treacherous waters. The pharmaceutical industry can be a challenging place to operate, as companies must spend $1 billion or more to develop a new drug and a majority of those that are put into... (full story)
Merck drops development of Endocyte cancer drug
AP - Tue Jun 17, 4:30PM CDT
NEW YORK (AP) — Biotech drugmaker Endocyte said Tuesday it has regained rights to an experimental cancer drug from Merck & Co., after the treatment failed in a key study last month. (full story)
Endocyte Regains Worldwide Rights to Vintafolide
GlobeNewswire - Tue Jun 17, 3:01PM CDT
Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no longer pursue development of vintafolide. (full story)
HPV Infections Vaccine Pipeline Analyzed by PNS Pharma in Its New Research Report Published at MarketPublishers.com
PRWeb - Tue Jun 17, 1:20PM CDT
Human papillomaviruses represent a group of over 150 viruses which are related to each other, with certain types of viruses being able to cause warts (papillomas). There exist only two human papillomavirus vaccines which are currently marketed worldwide. Both these vaccines are prepared with the use of the recombinant technology, which is taken from purified L1 structural proteins that self assemble to form HPV type-specific empty shells or virus-like particles (VLPs). (full story)
Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the... (full story)
The Zacks Analyst Blog Highlights: AbbVie, Gilead, Merck and Idenix Pharmaceuticals
PR Newswire - Tue Jun 17, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Gilead (Nasdaq:GILD-Free Report), Merck (NYSE:MRK-Free Report) and Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX-Free Report). (full story)
Global Respiratory Devices Market Report 2014: Inhalers, Nebulizers, Airways, Masks, Sleep Apnea, Oxygen Therapy, Ventilators Medical Humidifiers, Respiratory Measurement)
M2 - Tue Jun 17, 6:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hk98cb/the_worldwide) has announced the addition of the "The Worldwide Market for Respiratory Devices (Inhalers, Nebulizers, Airways, Masks, Sleep Apnea, Oxygen Therapy, Ventilators Medical Humidifiers, Respiratory Measurement)" report to their offering. The worldwide respiratory device market continues to grow despite economic downturns mainly due to the aging of the world population and increasing incidence of COPD. The market encompasses many different products to help treat and monitor respiratory conditions as well as many large and small manufacturers. This report provides exhaustive market coverage, including estimates and forecasts for the following devices: - Inhalers - Inhalers, device-only market - Nebulizers, Jet - Nebulizers, Ultrasonic - Airway Masks - Cannula - Tracheostomy Tubes - Sleep Apnea CPAP - Sleep Apnea Bi-Level - Sleep Apnea Facial Interface - Sleep Apnea APAP - Oxygen Concentrators - Oxygen Systems - Ventilators - Humidifiers - Respiratory Measurement Devices (Oximeters, Capnograph, Others) - Resuscitators Companies Profiled in this Report Include: - Airsep - Astrazeneca - Boehringer ingelheim gmbh - Covidien - Devilbiss Healthcare - Fisher & paykel healthcare - Ge healthcare - Glaxosmithkline - Invacare - Maquet medical systems - Medline - Merck & company, inc. - Omron healthcare - Pari respiratory equipment, inc. - Philips/respironics - Resmed - Smiths Medical - Spirometrics - Teleflex For more information visit http://www.researchandmarkets.com/research/hk..._worldwide (full story)
Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments
M2 - Tue Jun 17, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w4bxgz/healthcare) has announced the addition of the "Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments" report to their offering. Healthcare Associated Infection (HAI) Control Markets: Disinfection, Area, Sterilization, Device Sterilization, Testing-C.diff, Testing-MRSA, Treatments Infections from activities and procedures taking place within a healthcare facility have become a cause for great concern. These infection may occur in a postoperative wound or as a complication unrelated to the disease or condition. This report, Healthcare-Associated Infection (HAI) Control Markets: focuses on the market opportunities for companies that can assist hospitals and other healthcare facilities with important HAI mitigation tasks including: preventing, testing and treating infections in the healthcare environment. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20 or 5% of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions. This is driving the demand for products and services. Prevention, Testing and Treatment and will provide a market analysis for each of the important segments: - Disinfection - Wide-Area Sterilization - Device Sterilization - HAI Testing ' C.diff - HAI Testing ' MRSA - HAI Testing - Others - HAI Treatment 'Antibiotic Products As part of the report's coverage, the following trends are discussed: - Nosocomial Infection Statistics - Affordable Care Act (ACA) Funding - Populations at Risk for Infection - Infection Risk Assessments by Hospital Department - Increased Hospital Length of Stay for HAIs - International Trends in Nursing Facilities - U.S. Government's National Plan to Prevent Healthcare - Government Funding for HAI Prevention Infrastructure Activities - Israel Reduction in HAIs - Arizona Prevention Study - Connecticut Funding for HAI Prevention and Reporting - Pennsylvania Study of HAI Admissions and Readmissions - Infections and Drug Resistance - Screening Trends - Trends in Partnerships and Alliances - Current Burden of HAI Statistics The following companies are profiled in this report: - Advanced Sterilization Products - Becton, Dickinson and Company - Belimed - bioMerieux - Cantel - Cepheid - Getinge Group - Kimberly-Clark - Merck & Co - Nordion - Pfizer - Roche - Sakura Seiki - Steris - Tso3 For more information visit http://www.researchandmarkets.com/research/w4bxgz/healthcare (full story)
